



ARTICLE

# VACCINES AND ANTI-VAXXERS, THE CHALLENGE OF TRANSPARENT COMMUNICATION

SCIENCE VERSUS SKEPTICISM, FEAR AND FINANCIAL SPECULATION

Miami, August 13, 2020

# **INTRODUCTION**

In the history of public health, drinking water and vaccines are recognized as two great contributions toward for disease prevention for humanity. Without a doubt, vaccination considerably reduces morbidity, disability, mortality and inequality around the world, reducing poverty and closing gaps in social inequality.<sup>1</sup>

However, some skeptics, with no scientific basis, have become part of an anti-vaccine movement. Popular Spanish singer Miguel Bose drew attention to when he published a string of five anti-vaccine tweets that sought to halt COVID-19, the installation of 5G mobile phone antenna, Bill Gates and the Spanish government's cooperation with Gavi, the Vaccine Alliance (Gavi). According to Bose, he came out to the world as an anti-vaccine activist (an "anti-vaxxer") through this viral tweet, saying all these concepts have something in common – they form part of a supremacist plan "to obtain all sorts of information about the world's population in order to control people."

The World Health Organization (WHO) has classified anti-vaccine movements as a threat to the progress attained to date in fighting preventable diseases.<sup>2</sup>

Despite the scientific evidence that proves the efficacy and need for vaccines, the anti-vaccine movement has attracted great attention by promoting unfounded theories that some people find credible. For these followers and others, fear of mortal diseases has been replaced by fear of vaccines' secondary effects and the mistrust inspired by vaccination conspiracy theories. In fact, in a recent communication, the WHO and United Nations Children's Fund (UNICEF) warned of an alarming decline in vaccine use and the corresponding negative impact on public health.

Paradoxically, the need for a vaccine to tackle the COVID-19 pandemic places the value of vaccines at centerstage once more. Institutions, governments and companies are committed to developing a vaccine to not only to contain the disease, but also to alleviate the global economic problem caused by the pandemic. Financial speculation regarding progress on research into vaccines to combat COVID-19 has also surprised many people, leading pharmaceutical companies to impressive capitalization levels. According to figures from financial experts, five companies with vaccine candidates have increased their market capitalization by US\$50 billion.

# Share- price performance



Note: ADR performance shown for AstraZeneca and BionTech Source: FactSet

<sup>1</sup>OMS (2008). La vacunación reduce considerablemente la morbilidad, las discapacidades, la mortalidad y las inequidades en todo el mundo. Disponible en: https://www.who.int/bulletin/ volumes/86/2/07-040089-ab/es/

<sup>2</sup>https://www.who.int/news-room/feature-stories/ten-threatsto-global-health-in-2019

# GIVEN THIS, A SERIES OF QUESTIONS HAS ARISEN

• Is a new communications approach required to strengthen the social and economic benefit of vaccines?

• Is the anti-vaccine movement, which seeks to erode public institutions, achieving its goal?

• How can someone with full access to information come to believe that vaccines form part of the plan of an elite group seeking to control the world?

• What can companies and organizations do to incentivize vaccination?

• What communication and public opinion challenges are facing health authorities?

# BETWEEN THE SOCIAL BENEFIT AND THE ECONOMIC IMPACT

According to the WHO, Gavi and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), vaccines are the most cost-effective way to save lives and promote good health and wellbeing to prevent disease, death and incapacitation.

From the almost complete eradication of diseases such as polio to the successful distribution and mass application of the pentavalent vaccine that protects children from five diseases, vaccination has led to a generation of children with much greater chances of survival than previous generations had. At present, vaccination prevents 2-3 million deaths per year, and since 1990, it has managed to reduce the mortality rate in children under five by 52 percent.<sup>3</sup>

According to Gavi, more than \$150 trillion were generated in economic profit between 2000 and 2017. Furthermore, the WHO study that measured the economic impact of vaccination from 10 diseases in 73 countries between 2001 and 2020 concluded that immunizing the population would prevent more than 20 million deaths and save US\$350 billion in costs to treat diseases. In the case of the Americas, the Pan American Health Organization (PAHO) reports that six preventable diseases have been eradicated thanks to vaccination<sup>4</sup>, which shows the efficacy of vaccines and their social contribution.

A large number of scientific and health organizations have confirmed the value of vaccines. The Center for Disease Control and Prevention (CDC) highlights vaccines as being essential as safe and proven protection from disease, stressing that serious secondary effects after vaccination are extremely rare.<sup>5</sup>

"At present, vaccination prevents 2-3 million deaths per year, and since 1990, it has managed to reduce the mortality rate in children under five by 52 percent"

<sup>3</sup>OMS. (2019). Cobertura Vacunal. Disponible en: https:// www.who.int/docs/default-source/coronaviruse/situationreports/20200325-sitrep-65-COVID-19.pdf?sfvrsn=2b74edd8\_2

<sup>4</sup>OPS. Semana de Vacunación de las Américas 2020. Disponible en: https://www.paho.org/es/campa%C3%B1as/semanavacunacion-americas-2020

<sup>5</sup>https://www.cdc.gov/vaccines/parents/FAQs.html



# A CRY OF ALARM: DECLINE IN THE USE OF VACCINES

UNICEF and the WHO warned of the alarming reduction in the number of children in the world receiving essential vaccines. According to these organizations, this interruption in the supply of vaccines threatens to reverse the progress achieved in public health over recent decades and enhance the likelihood of future disease outbreaks. Many people reject vaccines on ideological grounds, due to a lack of confidence in health systems and medical staff or even oppose the introduction of substances to a healthy person's body. According to some medical experts, the coverage problems are more due to social exclusion and poverty than ideological reasons or anti-vaccine movements, since, according to data from the WHO, U.S. FDA and European Medication Agency, there is no evidence that vaccines cause autoimmune diseases or risk of death.

# COVID-19 HAS TURNED VACCINATION INTO A CHALLENGE

Despite all the proven benefits of vaccination for public health, things are not going well for manufacturers or organizations, and far less for the beneficiaries of vaccination. According to a survey carried out by UNICEF, the WHO and Gavi, three-quarters of the 82 countries that responded confirm that vaccination programs have been interrupted due to the problems caused by COVID-19. This is because of several factors, including people's inability to gain access to services, resistance to leaving home, the suspension of transport systems, economic difficulties and movement restrictions. The fear of the spread of SARS-CoV-2 is one of the main reasons behind the decline in visits to vaccination centers. However, immunization coverage dropped off by 85 percent for DTP and measles vaccines even before the emergence of COVID-19.

Preliminary data for the first four months of 2020 points to a significant decline in the number of children who complete the three doses of the vaccine against diphtheria, whooping cough and tetanus. This will be the first time in 28 years that the world has seen a decline in vaccines on this scale.

# INFLUENCE OF THE ANTI-VACCINE MOVEMENT

"I SAY NO TO VACCINATION, NO TO 5G, NO TO THE SPAIN ALLIANCE/BILL GATES. #YoSoyLaResistencia [I am the resistance]." These statements, made by Spanish singer Miguel Bose, seem to have been taken from a dystopian film. Thousands of people around the world, including health and religious groups, politicians and even scientists, claim that vaccines and vaccinations are more harmful to humanity than the benefits they can provide. The anti-vaccine movement is primarily growing on the internet, with activists at times including highly influential figures such as Donald Trump, Jim Carrey and Luc Montagnier, winner of the Nobel Prize for Medicine Prize in 2008.

The reality is that we are at a key moment in time for this type of movement. With so much information and misinformation moving so quickly, it is easy to get confused.

"The anti-vaccine movement is primarily growing on the internet, with activists at times including highly influential figures such as Donald Trump, Jim Carrey and Luc Montagnier"

# At what point did the anti-vaccine movement become so influential, both in terms of communications and current affairs?

Since Edward Jenner coined the term "vaccination" in the 18th century and proposed inoculating people with one virus to protect them from another, there have always been those who have sought to discredit the vaccination process. Hence, the origin of anti-vaxxers can be traced back to the birth of vaccination. This is not a new group in the life of society, since our way of thinking, based on duality, leads to a simple truth – if thing A exists, then an anti-thing A probably also exists. When you add the success of fake news or the post-truth phenomenon to this, we have the perfect breeding ground to generate doubt.

# **ANTI-SYSTEM ANTI-VACCINES**

Since its origins and until just a few years ago, the anti-vaccine movement has been a constant force, whether for religious, political, family, philosophical or other reasons. The debate around vaccination has also been present beyond stories of success or failure.<sup>6</sup> Being an anti-vaxxer has become a hallmark, specifically an antisystem identity.

When revising materials and theories on the main anti-vaccine campaigns, connective patterns emerge: Theories against 5G technology, a conspiracy of large pharmaceutical companies and the domination of renowned figures such as Bill Gates and George Soros, among others. The common denominator of all these narratives is that "the system" tries to control or manipulate people at large. Accordingly, a chain of beliefs is created which, when you accept one, leads you to believe in the others. For example, if someone begins to search for theories on 5G on Google, they will start to find arguments against vaccines and vice-versa. In other words, being anti-vaccine increasingly appears to be more anti-system.



Vaccines and anti-vaxxers, the challenge of transparent communication

Preliminary data on three potential vaccines were presented as positive at the end of July. Two studies, one by AstraZeneca and Oxford University and the other by the Chinese company CanSino, were published in the magazine The Lancet. Both show an immune response in most recipients of the experimental vaccine. In addition, the German company BioNTech and Pfizer reported that their vaccine candidate neutralized viral antibodies after two doses. U.S. company Moderna also reported on its preliminary results and has begun a final phase to test the vaccination's effectiveness against COVID-19. This pharmaceutical company's vaccine is the first outside of China to reach these levels; testing has now begun on 30,000 volunteers.

Many experts and pharmaceutical companies with long histories in the vaccination business have stated that it is too soon to draw conclusions from the data currently available, saying the phase the most advanced experimental vaccines are currently at is critical to showing security and efficacy in a large portion of the population. Some predict a vaccine may be available by mid-2021. Despite this, the price of AstraZeneca shares rose by 10 percent, but dropped to close at only 1.45 percent up from the opening price. Similar situations have occurred with other companies. Too much information is available about the preliminary results, and there is a great deal of speculation on the possibility of discovering a vaccine this year, as well as on its price and on who will have access to it.

# HOWEVER, THE WORLD IS WAITING FOR A VACCINE: PROGRESS

Now that we are facing an unprecedented pandemic, the world's attention is on the search for a vaccine to control the spread of the virus and how we can provide equal access to it. In a matter of months, some pharmaceutical companies developed research plans to find solutions using new technologies, harnessing public-private alliances. Laboratories, researchers and universities have mobilized to discover potential vaccine candidates, some of which are now undergoing clinical trials.

<sup>6</sup> https://www.historyofvaccines.org/content/articles/historyanti-vaccination-movements

# **IDEAS LLYC**


# Developing the vaccine is a challenge; convincing people to use it is another

A survey published by CNN in the United States indicated that one-third of North Americans surveyed would not use the vaccine against SARS-CoV-2, even if it were widely available. The results also showed that some people are skeptical of all types of vaccine, perhaps because the antivaccine movement has been successful. Others do not believe the vaccine will be safe because it is being developed in record time, while still more believe policy has contaminated the vaccine's development and are thus reluctant to use it. All of this could be due to lack of confidence in light of all the information and misinformation in circulation.

A new communications approach is necessary, and the health authorities must recover their leading role.

Aside from the presentation of the preliminary clinical results and increase in the market value of companies that research and manufacture vaccines, society must once again be convinced of the usefulness of vaccines. Companies must take advantage of this historic moment to reconsider their communications, because while it was previously the responsibility of governments to organize vaccine workshops and convince people to attend vaccination modules, this now requires an approach based on confidence, forging transparency and highlighting the value of science.

"One-third of North Americans surveyed would not use the vaccine against SARS-CoV-2, even if it were widely available"



# **OUR SEVEN RECOMMENDATIONS**

# 1. From a purpose to a shared purpose.

Many pharmaceutical companies must revise or redesign their corporate purposes with a higher-level perspective, based on the current environment in our societies. This demands more transparency in clinical research and information on the benefits of vaccines, as well as their potential risks.

# 2. Direct communication between

companies and potential vaccine users. Communication must be stepped up, not solely left in the hands of governments. This requires moving from dialogue to direct conversation. The new paradigm for companies' social leadership requires development, moving from a process of dialogue to genuine conversation through the creation of collaborative platforms and forums for collaboration and commitment. There, stakeholders can actively take part in the development of solutions, as well as ask and receive responses to their questions. If this is not available there, they will look for these answers from non-scientific sources or those not based on research.

# 3. From responsibility to commitment.

It will be necessary to develop good governance systems that evolve from regulatory commitment to knowledge and evaluation of stakeholder expectations, from the perspectives of both opportunity and reputational risk. This leads us to evaluate vaccines' cost-efficiency in reducing poverty gaps, and accordingly, lowering costs for health systems, creating savings and driving economic results. How many COVID-19type pandemics have we avoided thanks to vaccines?

4. Transparency in pricing and government agreements, as well as more public-private alliances. This allows quick progress to be made to prevent current and emerging health problems, also enabling joint communication campaigns to ensure the benefits of vaccination quickly reach as many people as possible. Companies must cover everything from value creation to the co-creation of sustainable value with stakeholders to convincing more people of the importance of vaccines.

# 5. Recover a long-term perspective.

Driving credibility regarding the reality of vaccines requires a new value proposal for each stakeholder. Different groups' interests converge in the long term, though they often collide in the short term. Hence their difficulty, and hence the need for a long-term perspective that COVID-19 could help audiences appreciate. A key pillar of responsible leadership that is being profiled is related to the management, communication and measurement of pharmaceutical companies' business impact on society.

# 6. From managing risks to managing

opportunities. Organizations that appreciate that the only constant is change will be capable of getting ahead of the game and harnessing the new opportunities that arise alongside new changes. Anti-vaxxers have created a risk; now, the industry needs to find a way to respond and tackle these risks using transparent, specific information.

# 7. Systemize management in the search for

**excellence.** This systemization works when a management system is created to search for excellence on an ongoing basis – a passionate challenge that requires people with vision and aspirations of creating a legacy. The pharmaceutical and vaccine industries have left a legacy that is key to clearly exemplify while also demonstrating the contributions vaccines have made toward creating the present (and future) wellbeing of society.

# v in

# AUTHORS

Alejandro Romero. Partner and CEO for the Americas at LLYC. Ever since 1997 Romero has been at the forefront of the company's expansion processes in Latin America, starting operations in Peru, Argentina, Colombia, Panama, Ecuador, Mexico and recently, Miami. Romero has also recently led the communication processes in three of the ten most important M&A operations in the region: the selling of BellSouth operations to the Telefonica Group; SABMiller's acquisition of the Corporate Group Bavaria and; the selling of the Financial Group Uno to Citibank. In 20 years, Romero has managed to position LLYC as the leading communication network in Latin America.

# aromero@llorenteycuenca.com



Javier Marín. Director Senior Healthcare Américas. Javier Marin is a communication and public affairs professional with experience in both the public and private sectors, as well as over 20 years of experience at pharmaceutical, biotech and life science companies. During the course of his career, he developed social communication campaigns on disease prevention and health care for the Mexican government; corporate communication, governmental affairs, and internal, marketing, digital and CSR communication, as well as relationship programs with patient groups at a local level in Mexico, throughout Latin America and worldwide at companies such as Merck & Co. (MSD) and Johnson & Johnson.

# jmarin@llorenteycuenca.com

This article was written in collaboration with Fernando Arreaza, Senior Consultant at LLYC Miami, and Julieta Rodríguez, Senior Consultant at LLYC Colombia.

# **IDEAS LLYC**

# MANAGEMENT TEAM

Iosé Antonio Llorente unding Partner and Chairman jallorente@llorenteycuenca.com

Alejandro Romero Partner and CEO Americas aromero@llorentevcuenca.com

Enrique González Partner and CFO egonzalez@llorenteycuenca.com

Adolfo Corujo Partner and Chief Strategy and Innovation Officer acorujo@llorenteycuenca.com

Nazaret Izquierdo Chief Talent Office nizquierdo@llorentevcuenca.com

Cristina Ysasi-Ysasmendi Corporate Directo cysasi@llorenteycuenca.com

Juan Pablo Ocaña Director, Legal & Compliance jpocana@llorenteycuenca.com

Daniel Fernández Trejo Senior Director, Technology dfernandez@llorenteycuenca.com

José Luis Di Girolamo Partner and Global Controller jldgirolamo@llorenteycuenca.com

Antonieta Mendoza de López Vice President, Advocacy LatAm amendozalopez@llorenteycuenca.com

# SPAIN AND PORTUGAL

Arturo Pinedo Partner and Managing Director apinedo@llorenteycuenca.com

Luisa García Partner and Managing Director lgarcia@llorenteycuenca.com

# Barcelona

María Cura Partner and Managing Director mcura@llorenteycuenca.com

Óscar Iniesta Partner and Senior Director oiniesta@llorenteycuenca.com

Muntaner, 240-242, 1º-1ª 08021 Barcelona Tel. +34 93 217 22 17

# Madrid

Ioan Navarro Partner and Vicepresident, Public Affairs inavarro@llorenteycuenca.com

Amalio Moratalla Partner and Senior Director, Sport and Business Strategy amoratalla@llorenteycuenca.com

Iván Pino Partner and Senior Director, Digital ipino@llorenteycuenca.com

David G. Natal Partner and Senior Director, Consumer Engagement dgonzalezn@llorenteycuenca.com

Ana Folgueira Partner and Executive Manager of the Creative Studio afolgueira@llorenteycuenca.com

Paco Hevia Senior Director, Corporate Communication phevia@llorenteycuenca.com

Jorge López Zafra Senior Director, Financial Communication jlopez@llorenteycuenca.com

Lagasca, 88 - planta 3 28001 Madrid Tel. +34 91 563 77 22

# Lisbon

Tiago Vidal Partner and Managing Director tvidal@llorentevcuenca.com

Avenida da Liberdade nº225, 5º Esq. 1250-142 Lisboa Tel. + 351 21 923 97 00

### UNITED STATES

Erich de la Fuente rtner and Chairn edelafuente@llorenteycuenca.com

**Carlos Correcha-Price** CEO ccorrecha@llorenteycuenca.com

Javier Marín enior Director, Healthcare Americas jmarin@llorenteycuenca.com

### Miami

Emigdio Rojas utive Dire erojas@llorenteycuenca.com

### New York City

Gerard Guiu Director, International Business Development gguiu@llorenteycuenca.com

3 Columbus Circle 9th Floor New York, NY 10019 United States Tel. +1 646 805 2000

Santo Domingo

Tel. +507 206 5200

Iban Campo Managing Director icampo@llorenteycuenca.com

NORTH REGION

Partner and Regional Managing Director

jrosado@llorenteycuenca.com

rblanco@llorenteycuenca.com

Av. Paseo de la Reforma 412

CP 06600, Ciudad de México

jmarin@llorenteycuenca.com

Manuel Domínguez

Senior Director, Healthcare Americas

Piso 14. Colonia Iuárez

Tel. +52 55 5257 1084

lavier Marín

Panama City

Alcaldía Cuauhtémor

lavier Rosado

Mexico City

Rogelio Blanco

Managing Director

Av. Abraham Lincoln 1069 Torre Ejecutiva Sonora, planta 7 Suite 702 Tel. +1 809 6161975

### San Jose

Pablo Duncan - Linch Partner and Director CLC Comunicación | Afiliada LLYC pduncan@clcglobal.cr

Del Banco General 350 metros oeste Trejos Montealegre, Escazú San José Tel. +506 228 93240

### ANDEAN REGION

Luis Miguel Peña Partner and Regional Managing Director

### Bogota

María Esteve Partner and Managing Director mesteve@llorenteycuenca.com

Av. Calle 82 # 9-65 Piso 4 Bogotá D.C. – Colombia Tel. +57 1 7438000

### Lima

Gonzalo Carranza Managing Director gcarranza@llorenteycuenca.com

Av. Andrés Reyes 420, piso 7 San Isidro Tel. +51 1 2229491

Managing Director mdominguez@llorenteycuenca.com Ouito

**Carlos Llanos** Sortis Business Tower Piso 9, Calle 57 Obarrio - Panamá Managing Director cllanos@llorenteycuenca.com

> Avda. 12 de Octubre N24-528 y Cordero – Edificio World Trade Center – Torre B - piso 11 Tel. +593 2 2565820

# Santiago de Chile

Marcos Sepúlveda Managing Director msepulveda@llorenteycuenca.com

Francisco Aylwin Chairman

faylwin@llorenteycuenca.com Magdalena 140, Oficina 1801

Las Condes Tel. +56 22 207 32 00

# ideas.llorenteycuenca.com

**Juan Carlos Gozzer** . Partner and Regional Managing

Director Impena@llorenteycuenca.com jcgozzer@llorenteycuenca.com

**Cleber Martins** Partner and Managing Director clebermartins@llorentevcuenca.com

SOUTH REGION

Rua Oscar Freire, 379, Cj 111 Cergueira César SP - 01426-001 Tel. +55 11 3060 3390

### Rio de Janeiro

Sao Paulo

**Cleber Martins** Partner and Managing Director clebermartins@llorentevcuenca.com

Rua Oscar Freire, 379, Cj 111 Cergueira César SP - 01426-001 Tel. +55 11 3060 3390

### **Buenos** Aires

Mariano Vila Partner and Managing Director mvila@llorenteycuenca.com

Av. Corrientes 222, piso 8 C1043AAP Tel. +54 11 5556 0700



# **IDEAS LLYC**

EXPLORE. INSPIRE.

IDEAS by LLYC is a hub for ideas, analysis and trends. It is a product of the changing macroeconomic and social environment we live in, in which communication keeps moving forward at a fast pace.

IDEAS LLYC is a combination of global partnerships and knowledge exchange that identifies, defines and communicates new information paradigms from an independent perspective. Developing Ideas is a constant flow of ideas, foreseeing new times for information and management.

Because reality is neither black nor white, IDEAS LLYC exists.

ideas.llorenteycuenca.com www.uno-magazine.com